Fostroxacitabine bralpamide(Synonyms: MIV-818)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Fostroxacitabine bralpamide (Synonyms: MIV-818)

Fostroxacitabine bralpamide (MIV-818) 是一种具有口服活性的基于 Troxacitabine 的核苷酸前药，具有抗癌作用。

Fostroxacitabine bralpamide(Synonyms: MIV-818)

Fostroxacitabine bralpamide Chemical Structure

CAS No. : 2129993-56-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Fostroxacitabine bralpamide (MIV-818) is an orally active Troxacitabine-based nucleotide prodrug. Fostroxacitabine bralpamide has anticancer effects[1].

体外研究
(In Vitro)

Fostroxacitabine bralpamide (MIV-818) is highly metabolized by human hepatocytes, directing high levels of the chain-terminating nucleotide tri-phosphate to the liver. The tri-phosphate is incorporated into DNA during replication, which leads to DNA double strand breaks, DNA damage responses, and cytotoxicity[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

589.37

Formula

C22H30BrN4O8P
CAS 号

2129993-56-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. T.R. Jeffry Evans, et al. Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务